A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo

References

• Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72: 3666–70
   PubMed Web of Science ®Google Scholar
• Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 630–2
   PubMed Web of Science ®Google Scholar
• Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res 1988; 48: 2179–83
   PubMed Web of Science ®Google Scholar
• Folli S, Pelegrin A, Chalandon Y, et al. Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability. Int J Cancer 1993; 53: 829–36
   PubMed Web of Science ®Google Scholar
• Hagen TL, Eggermont AM. Solid tumor therapy: manipulation of the vasculature with TNF. Technol Cancer Res Treat 2003; 2: 195–203
   PubMed Web of Science ®Google Scholar
• Haranaka K, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984; 34: 263–7
   PubMed Web of Science ®Google Scholar
• Sasaki Y, Kanzawa F, Takahashi H, et al. In vitro antitumor effect of recombinant human tumor necrotizing factor on cultured human cancer cell lines and freshly isolated lung cancer cells by the human tumor clonogenic assay. Invest New Drugs 1987; 5: 353–9
   PubMed Web of Science ®Google Scholar
• Blick M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986–9
   PubMed Web of Science ®Google Scholar
• Kimura K, Taguchi T, Urushizaki I, et al. Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1987; 20: 223–9
   PubMed Web of Science ®Google Scholar
• Kemeny N, Childs B, Larchian W, et al. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma. Cancer 1990; 66: 659–63
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-α in cancer. Curr Opin Immunol 1998; 10: 573–80
   PubMed Web of Science ®Google Scholar
• Jones AL, Selby P. Tumour necrosis factor: clinical relevance. Cancer Surv 1989; 8: 817–36
   PubMedGoogle Scholar
• Wiedenmann B, Reichardt P, Rath U, et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 1989; 115: 189–92
   PubMed Web of Science ®Google Scholar
• Bartsch HH, Pfizenmaier K, Schroder M, Nagel GA. Systemic versus local therapy with recombinant tumor necrosis factor-α (r-TNF-α) in patients with advanced tumors. Oncology 1989; 12: 136–41
   Google Scholar
• Mavligit GM, Zukiwski AA, Charnsangavej C, et al. Regional biologic therapy. Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases. Cancer 1992; 69: 557–61
   PubMed Web of Science ®Google Scholar
• Nakamura A, Kato A, Masegi T. , et al A novel recombinant tumor necrosis factor-α mutant with increased anti-tumor activity and lower toxicity. Int J Cancer 19914;8:744–8.
   Google Scholar
• Ostade XV, Vandenabeele P, Everaerdt B, et al. Human TNF mutants with selective activity on the p55 receptor. Nature 1993; 361: 266–9
   PubMed Web of Science ®Google Scholar
• Reed C, Fu ZQ, Wu J, et al. Crystal structure of TNF-α mutant R31D with greater affinity for receptor R1 compared with R2. Protein Eng 1997; 10: 1101–07
   PubMedGoogle Scholar
• Shin NK, Lee I, Chang SG, Shin HC. A novel tumor necrosis factor-α mutant with significantly enhanced cytotoxicity and receptor binding affinity. Biochem Mol Biol Int 1998; 44: 1075–82
   PubMedGoogle Scholar
• Cha SS, Kim JS, Cho HS, et al. High resolution crystal structure of a human tumor necrosis factor-α mutant with low systemic toxicity. J Biol Chem 1998; 273: 2153–60
   PubMed Web of Science ®Google Scholar
• Kuroda K, Miyata K, Fujita F, et al. Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice. Cancer Lett 2000; 159: 33–41
   PubMed Web of Science ®Google Scholar
• Zhang ZQ, Yao LH, Hou YD. Construction and application of a high level expression vector containing PRPL promoter. Chinese J Virol 1990; 6: 111–16
   Google Scholar
• Yan Z, Zhang YQ, Li M, Cheng CQ. Fermentation research of new type recombinant human tumor necrosis factor α. Chinese J Biochem Pharm 2001; 22: 64–7
   Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–75
   PubMed Web of Science ®Google Scholar
• Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5
   PubMed Web of Science ®Google Scholar
• Fransen L, Van der Heyden J, Ruysschaert R, Fiers W. Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986; 22: 419–26
   PubMedGoogle Scholar
• Beyaert R, Fiers W. Molecular mechanisms of tumor necrosis factor-induced cytotoxicity. What we do understand and what we do not. FEBS Lett 1994; 340: 9–16
   PubMed Web of Science ®Google Scholar
• Liu ZG, Han J. Cellular responses to tumor necrosis factor. Curr Issues Mol Biol 2001; 3: 79–90
   PubMedGoogle Scholar
• Lu Y, Yamauchi N, Koshita Y, et al. Administration of subtumor regression dosage of TNF-alpha to mice with pre-existing parental tumors augments the vaccination effect of TNF gene-modified tumor through the induction of MHC class I molecule. Gene Ther 2001; 8: 499–507
   PubMed Web of Science ®Google Scholar
• Curnis F, Sacchi A, Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest 2002; 110: 475–82
   PubMed Web of Science ®Google Scholar
• Kamijo R, Takeda K, Nagumo M, et al. Induction of differentiation of human monoblastic and myeloblastic leukemia cell lines by TNF muteins. Biochem Biophys Res Commun 1989; 160: 820–7
   PubMed Web of Science ®Google Scholar
• Hagen TL, Eggermont AM. Tumor vascular therapy with TNF: critical review on animal models. Methods Mol Med 2004; 98: 227–46
   PubMedGoogle Scholar
• Curnis F, Gasparri A, Sacchi A, et al. Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 2004; 64: 565–71
   PubMed Web of Science ®Google Scholar
• Lejeune FJ. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest 2002; 110: 433–5
   PubMed Web of Science ®Google Scholar